Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed its fiscal 2025 10-K annual report with the SEC on Mar 2, 2026. It reported revenue of $292M (+43.7% year over year) and net income of $554,000.
- Top risk flagged: Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
FY2025 key financial metrics · XBRL
- Revenue
- $292M
- +43.7% YoY
- Net income
- $554,000
- +101.0% YoY
- Operating margin
- 8.5%
- +25.1 pp YoY
- EPS (diluted)
- $0.00
- +100.0% YoY
- ROE
- 4.0%
- −181.1 pp YoY
- Operating cash flow
- $29M
- +177.4% YoY
Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) FY2025 10-K on SEC EDGAR. USD.
Xeris Biopharma Holdings, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
- Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
- Strategic emphasis on pipeline leveraging proprietary non-aqueous formulation tech (XeriSol/XeriJect) for improved drug delivery and new licensing partnerships
- Patent protection for key products: Recorlev (orphan drug exclusivity through 2028, patents to 2040), Gvoke patents to 2036; Keveyis lost orphan exclusivity in 2022, facing generic competition
- Noteworthy: Positive Phase 2 data for XP-8121 with 72% patient preference for weekly injection; FDA agreed on single non-inferiority Phase 3 trial design
Management Discussion & Analysis
- Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
- Investing cash outflow $696K in 2025 vs inflow $4.9M in 2024 due to fewer short-term investment purchases
Risk Factors
- Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
- Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
- Supply chain and inventory risks with potential product returns exceeding reserves, reliant on third-party data accuracy for return estimates
- Competitive threats to Recorlev from Corcept Therapeutics' Korlym, Recordati's Signifor LAR and Isturisa, and potential ketoconazole approval in US
- Financial risk from $200M term loans and $33.6M 8.00% Convertible Notes secured by company assets, with restrictive covenants limiting operations
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.